[1]
|
汪凯, 董强, 郁金泰, 等. 卒中后认知障碍管理专家共识2021 [J]. 中国卒中杂志, 2021, 16(4): 376-389.
|
[2]
|
Almalki, O., Alshehri, M.A., El-Sodany, A.M., et al. (2018) The Awareness of Healthcare Staff towards Post-Stroke Cognitive Impairment: A Cross Sectional Study. The Journal of Physical Therapy Science, 30, 883-887.
https://doi.org/10.1589/jpts.30.883
|
[3]
|
Zhang, X. and Bi, X. (2020) Post-Stroke Cognitive Impairment: A Review Focusing on Molecular Biomarkers. Journal of Molecular Neuroscience, 70, 1244-1254. https://doi.org/10.1007/s12031-020-01533-8
|
[4]
|
Dziedzic, T. (2015) Systemic Inflammation as a Therapeutic Target in Acute Ischemic Stroke. Expert Review of Neurotherapeutics, 15, 523-531. https://doi.org/10.1586/14737175.2015.1035712
|
[5]
|
Lee, M., Lim, J.S., Kim, C.H., et al. (2021) High Neutro-phil-Lymphocyte Ratio Predicts Post-Stroke Cognitive Impairment in Acute Ischemic Stroke Patients. Frontiers in Neurology, 12, Article ID: 693318.
https://doi.org/10.3389/fneur.2021.693318
|
[6]
|
Nam, K.W., Kwon, H.M., Jeong, H.Y., et al. (2018) High Neu-trophil to Lymphocyte Ratios Predict Intracranial Atherosclerosis in a Healthy Population. Atherosclerosis, 269, 117-121.
https://doi.org/10.1016/j.atherosclerosis.2017.12.035
|
[7]
|
Suh, B., Shin, D.W., Kwon, H.M., et al. (2017) Elevated Neutrophil to Lymphocyte Ratio and Ischemic Stroke Risk in Generally Healthy Adults. PLOS ONE, 12, e0183706. https://doi.org/10.1371/journal.pone.0183706
|
[8]
|
Qun, S., Tang, Y., Sun, J., et al. (2017) Neutro-phil-to-Lymphocyte Ratio Predicts 3-Month Outcome of Acute Ischemic Stroke. Neurotoxicity Research, 31, 444-452. https://doi.org/10.1007/s12640-017-9707-z
|
[9]
|
Kunutsor, S.K. (2016) Gamma-Glutamyltransferase-Friend or Foe within? Liver International, 36, 1723-1734.
https://doi.org/10.1111/liv.13221
|
[10]
|
Gasecka, A., Siwik, D., Gajewska, M., et al. (2020) Early Biomarkers of Neurodegenerative and Neurovascular Disorders in Diabetes. Journal of Clinical Medicine, 9, Article No. 2807. https://doi.org/10.3390/jcm9092807
|
[11]
|
Hong, S.H., Han, K., Park, S., et al. (2020) Gamma-Glutamyl Transfer-ase Variability and Risk of Dementia in Diabetes Mellitus: A Nationwide Population-Based Study. The Journal of Clinical Endocrinology & Metabolism, 105, dgaa019. https://doi.org/10.1210/clinem/dgaa019
|
[12]
|
Lee, Y.B., Han, K., Park, S., et al. (2020) Gamma-Glutamyl Transferase Variability and Risk of Dementia: A Nationwide Study. International Journal of Geriatric Psychiatry, 35, 1105-1114. https://doi.org/10.1002/gps.5332
|
[13]
|
Praetorius, B.M. and Johansson, B. (2018) Gamma-Glutamyltransferase (GGT) as a Biomarker of Cognitive Decline at the End of Life: Contrasting Age and Time to Death Trajectories. International Psychogeriatrics, 30, 981-990.
https://doi.org/10.1017/S1041610217002393
|
[14]
|
Li, S., Liao, X., Pan, Y., et al. (2022) Gamma-Glutamyl Transferase Levels Are Associated with the Occurrence of Post-Stroke Cognitive Impairment: A Multicenter Cohort Study. BMC Neurology, 22, Article No. 65.
https://doi.org/10.1186/s12883-022-02587-4
|
[15]
|
Nagata, T., Ohara, T., Hata, J., et al. (2019) NT-proBNP and Risk of Dementia in a General Japanese Elderly Population: The Hisayama Study. Journal of the American Heart As-sociation, 8, e011652.
https://doi.org/10.1161/JAHA.118.011652
|
[16]
|
Zhu, Y., Fang, C., Zhang, Q., et al. (2021) Soluble ST2 and Risk of Cognitive Impairment after Acute Ischemic Stroke: A Prospective Observational Study. BMC Geriatrics, 21, Article No. 330. https://doi.org/10.1186/s12877-021-02288-6
|
[17]
|
Andersson, C., Preis, S.R., Beiser, A., et al. (2015) Associations of Circulating Growth Differentiation Factor-15 and ST2 Concentrations with Subclinical Vascular Brain Injury and Incident Stroke. Stroke, 46, 2568-2575.
https://doi.org/10.1161/STROKEAHA.115.009026
|
[18]
|
Tian, X., Guo, Y., Wang, X., et al. (2020) Serum Soluble ST2 Is a Potential Long-Term Prognostic Biomarker for Transient Ischaemic Attack and Ischaemic Stroke. European Journal of Neurology, 27, 2202-2208.
https://doi.org/10.1111/ene.14419
|
[19]
|
Matilla, L., Ibarrola, J., Arrieta, V., et al. (2019) Soluble ST2 Promotes Oxidative Stress and Inflammation in Cardiac Fibroblasts: An in Vitro and in Vivo Study in Aortic Stenosis. Clinical Science (London), 133, 1537-1548.
https://doi.org/10.1042/CS20190475
|
[20]
|
Dieplinger, B., Bocksrucker, C., Egger, M., et al. (2017) Prognostic Value of Inflammatory and Cardiovascular Biomarkers for Prediction of 90-Day All-Cause Mortality after Acute Is-chemic Stroke-Results from the Linz Stroke Unit Study. Clinical Chemistry, 63, 1101-1109. https://doi.org/10.1373/clinchem.2016.269969
|
[21]
|
Wolcott, Z., Batra, A., Bevers, M.B., et al. (2017) Soluble ST2 Predicts Outcome and Hemorrhagic Transformation after Acute Stroke. Annals of Clinical and Translational Neurology, 4, 553-563. https://doi.org/10.1002/acn3.435
|
[22]
|
Wang, Z., Wang, R., Li, Y., et al. (2021) Plasma Neurofilament Light Chain as a Predictive Biomarker for Post-Stroke Cognitive Impairment: A Prospective Cohort Study. Frontiers in Aging Neuroscience, 13, Article ID: 631738.
https://doi.org/10.3389/fnagi.2021.631738
|
[23]
|
Guedes, V.A., Kenney, K., Shahim, P., et al. (2020) Exosomal Neurofilament Light: A Prognostic Biomarker for Remote Symptoms after Mild Traumatic Brain Injury? Neurology, 94, e2412-e2423.
https://doi.org/10.1212/WNL.0000000000009577
|
[24]
|
Gattringer, T., Pinter, D., Enzinger, C., et al. (2017) Serum Neurofilament Light Is Sensitive to Active Cerebral Small Vessel Disease. Neurology, 89, 2108-2114. https://doi.org/10.1212/WNL.0000000000004645
|
[25]
|
Liu, D., Chen, J., Wang, X., et al. (2020) Serum Neurofilament Light Chain as a Predictive Biomarker for Ischemic Stroke Outcome: A Systematic Review and Me-ta-Analysis. Journal of Stroke and Cerebrovascular Diseases, 29, Article ID: 104813. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.104813
|
[26]
|
Olsson, B., Portelius, E., Cullen, N.C., et al. (2019) Association of Cerebrospinal Fluid Neurofilament Light Protein Levels with Cognition in Patients with Dementia, Motor Neuron Disease, and Movement Disorders. JAMA Neurology, 76, 318-325. https://doi.org/10.1001/jamaneurol.2018.3746
|
[27]
|
Jay, T.R., Von Saucken, V.E. and Landreth, G.E. (2017) TREM2 in Neurodegenerative Diseases. Molecular Neurodegeneration, 12, Article No. 56. https://doi.org/10.1186/s13024-017-0197-5
|
[28]
|
Konishi, H. and Kiyama, H. (2018) Microglial TREM2/DAP12 Signaling: A Double-Edged Sword in Neural Diseases. Frontiers in Cellular Neuroscience, 12, Article No. 206. https://doi.org/10.3389/fncel.2018.00206
|
[29]
|
Deczkowska, A., Weiner, A. and Amit, I. (2020) The Physiology, Pathology, and Potential Therapeutic Applications of the TREM2 Signaling Pathway. Cell, 181, 1207-1217. https://doi.org/10.1016/j.cell.2020.05.003
|
[30]
|
Gervois, P. and Lambrichts, I. (2019) The Emerging Role of Triggering Receptor Expressed on Myeloid Cells 2 as a Target for Immunomodulation in Ischemic Stroke. Frontiers in Immunology, 10, Article No. 1668.
https://doi.org/10.3389/fimmu.2019.01668
|
[31]
|
Zhong, L. and Chen, X.F. (2019) The Emerging Roles and Ther-apeutic Potential of Soluble TREM2 in Alzheimer’s Disease. Frontiers in Aging Neuroscience, 11, Article No. 328. https://doi.org/10.3389/fnagi.2019.00328
|
[32]
|
Kwon, H.S., Lee, D., Lee, M.H., et al. (2020) Post-Stroke Cognitive Impairment as an Independent Predictor of Ischemic Stroke Recurrence: PICASSO Sub-Study. Journal of Neurology, 267, 688-693.
https://doi.org/10.1007/s00415-019-09630-4
|
[33]
|
Ohara, T., Hata, J., Tanaka, M., et al. (2019) Serum Soluble Triggering Receptor Expressed on Myeloid Cells 2 as a Biomarker for Incident Dementia: The Hisayama Study. Annals of Neurology, 85, 47-58.
https://doi.org/10.1002/ana.25385
|
[34]
|
Zhu, Y., Zhao, Y., Lu, Y., et al. (2022) The Association between Plasma Soluble Triggering Receptor Expressed on Myeloid Cells 2 and Cognitive Impairment after Acute Ischemic Stroke. Journal of Affective Disorders, 299, 287-293.
https://doi.org/10.1016/j.jad.2021.12.011
|
[35]
|
Keasey, M.P., Scott, H.L., Bantounas, I., et al. (2016) MiR-132 Is Upregulated by Ischemic Preconditioning of Cultured Hippocampal Neurons and Protects Them from Subsequent OGD Toxicity. Journal of Molecular Neuroscience, 59, 404-410. https://doi.org/10.1007/s12031-016-0740-9
|
[36]
|
Schöler, N., Langer, C., Döhner, H., et al. (2010) Serum mi-croRNAs as a Novel Class of Biomarkers: A Comprehensive Review of the Literature. Experimental Hematology, 38, 1126-1130.
https://doi.org/10.1016/j.exphem.2010.10.004
|
[37]
|
Reid, G., Kirschner, M.B. and Van Zandwijk, N. (2011) Cir-culating microRNAs: Association with Disease and Potential Use as Biomarkers. Critical Reviews in Oncolo-gy/Hematology, 80, 193-208.
https://doi.org/10.1016/j.critrevonc.2010.11.004
|
[38]
|
Huang, S., Zhao, J., Huang, D., et al. (2016) Serum miR-132 Is a Risk Marker of Post-Stroke Cognitive Impairment. Neuroscience Letters, 615, 102-106. https://doi.org/10.1016/j.neulet.2016.01.028
|
[39]
|
Balakathiresan, N., Bhomia, M., Chandran, R., et al. (2012) MicroRNA Let-7i Is a Promising Serum Biomarker for Blast-Induced Traumatic Brain Injury. Journal of Neurotrauma, 29, 1379-1387. https://doi.org/10.1089/neu.2011.2146
|
[40]
|
Bhomia, M., Balakathiresan, N.S., Wang, K.K., et al. (2016) A Panel of Serum MiRNA Biomarkers for the Diagnosis of Severe to Mild Traumatic Brain Injury in Humans. Scientific Reports, 6, Article No. 28148.
https://doi.org/10.1038/srep28148
|
[41]
|
Tabner, B.J., El-Agnaf, O.M., Turnbull, S., et al. (2005) Hydrogen Per-oxide Is Generated during the Very Early Stages of Aggregation of the Amyloid Peptides Implicated in Alzheimer Disease and Familial British Dementia. Journal of Biological Chemistry, 280, 35789-35792. https://doi.org/10.1038/srep28148
|
[42]
|
Wang, Z.Q., Li, K., Huang, J., et al. (2021) Corrigendum: MicroRNA Let-7i Is a Promising Serum Biomarker for Post-Stroke Cognitive Impairment and Alleviated OGD-Induced Cell Damage in Vitro by Regulating Bcl-2. Frontiers in Neuroscience, 15, Article ID: 648121. https://doi.org/10.3389/fnins.2021.648121
|